OGS signs proteomics deal with Glaxo

Oxford GlycoSciences closed a pharmacoproteomics deal with Glaxo (GLX; LSE:GLXO) to identify multi-disease biomarkers using OGS's high throughput proteomics platform. GLX will fund the protein researc...